State-of-the-Art Care for Patients With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas

Learn how the experts are leveraging the most recent data and incorporating novel targeted therapy to manage pediatric patients with neurofibromatosis type 1 plexiform neurofibromas with these downloadable slides podcast and on-demand webcast capturing a live CCO webinar.

Share

Program Content

Activities

MEK inhibitors for NF1 PN
A Targeted Therapy Approach to Improving Patient Outcomes in NF1
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 22, 2021

Expires: June 21, 2022

Management of NF1
Pathophysiology and Management of NF1
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 22, 2021

Expires: June 21, 2022

<i>EP</i>: Plexiform neurofibromas in NF1
Express Points
State-of-the-Art Care for Patients With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 23, 2021

Expires: June 22, 2022

No activities added yet

Activities

Q&A: MEKi in NF1
Expert Answers to Questions on Managing Neurofibromatosis Type 1 and MEK Inhibitors for NF1-Associated Plexiform Neurofibromas
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: July 12, 2021

Expires: July 11, 2022

Podcast Pearls: NF1
Podcast Pearls: Expert Answers to Questions on Neurofibromatosis Type 1 (NF1) and Plexiform Neurofibromas
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: July 12, 2021

Expires: July 11, 2022

Activities

NF1 Challenges
Real-World Challenges With MEK Inhibitors for NF1-Related Plexiform Neurofibromas
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: August 02, 2021

Expires: August 01, 2022

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

AstraZeneca